Achilles Therapeutics plc (MUN: 698)
Health Care · Biotechnology · GB
€—
— today · — 1Y
Achilles Therapeutics plc (MUN: 698) operates in the Biotechnology industry within the Health Care sector.
trading between 0.65 and 1.44.
Tweenvest scores Achilles Therapeutics plc across four factors: quality 28/100. Its strongest factor is quality.
698 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.66
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- €1.44
- 52-week low
- €0.65
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 204
- Next earnings
- —
About Achilles Therapeutics plc
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
- Founded
- 2016
- Listed since
- Mar 31, 2021
- Exchange
- Boerse Muenchen
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.63 | +0.25% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.01 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.08 | -2.06% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.